TriLink BioTechnologies, a Maravai LifeSciences company, has partnered with Avantor, Inc. to expand the availability of its innovative nucleic acid products across Europe, Middle East, and Africa (EMEA). This distribution agreement is designed to improve the ordering process and offer shorter lead times for European customers.
The partnership will make a wide range of TriLink's products more accessible in the EMEA region, including its CleanCap® cap analogs, catalog mRNAs, over 150 modified and unmodified nucleotides, and high-performance IVT enzymes like CleanScribe® RNA Polymerase. These products are available for research use only (RUO) or manufactured at GMP-grade.
By leveraging Avantor's extensive distribution network, this collaboration aims to better serve the growing demand for innovative solutions in the region and support the advancement of life-changing therapeutic research. TriLink products will also be available through VWR’s eCommerce platform, MarketSource, in the coming months.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.